Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies

• Published in: Archives of pharmacal research 2024, 47(4), , pp.301-324
• Main Authors: Zheng, Youle, Feng, Jin, Yu, Yixin, Ling, Min, Wang, Xu
• Format: Article
• Language: English
• Subjects: Animals; Drug Development - methods; Humans; Medicine; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Myostatin - antagonists & inhibitors; Myostatin - metabolism; Pharmacology/Toxicology; Pharmacy; Review; Sarcopenia - drug therapy; Sarcopenia - metabolism; Sarcopenia - therapy; 약학
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-024-01493-2

Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in managing sarcopenia. However, it is important to consider the variable efficacy and potential side effects associated with these treatments. There are currently no drugs approved by the Food and Drug Administration for sarcopenia. The ongoing research aims to develop more effective strategies in the future. Our review of research on disease mechanisms and drug development will be a valuable contribution to future research endeavors.